GlassScriptPhysician profile
Thomas W Mieras
NPI 1578564787
$13,114.34
in general payments reported to CMS, 2019-2025
55 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,066 · 2020: $1,521 · 2021: $2,043 · 2022: $2,440 · 2023: $2,715 · 2024: $1,268 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,809.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,514.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,266.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,207.24 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,036.42 | 2019-2025 | Repatha, Otezla, Evenity |
| Daiichi Sankyo INC. | $830.42 | 2020-2025 | Injectafer |
| Pfizer INC. | $554.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.66 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Merck Sharp & Dohme LLC | $495.75 | 2019-2024 | Steglatro, Belsomra, Steglujan |
| Janssen Pharmaceuticals, INC | $494.60 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $361.70 | 2020-2025 | Shingrix, Arexvy, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $287.54 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $283.44 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $239.84 | 2022 | |
| Esperion Therapeutics, INC. | $224.79 | 2020-2024 | Nexletol |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mieras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.